目的：观察抗纤益心方对扩张型心肌病患者心脏大小及心功能的影响。方法：将85 例患者随机分为治疗组43 例，对照组42 例（死亡1 例），两组均进行常规西药治疗，此外治疗组加服抗纤益心方汤剂，日1 剂。6 个月后观察超声左室舒张末内径、左房内径、射血分数及缩短分数变化。结果：两组均能减少左室舒张末内径、左心房内径，尤以治疗组明显（P＜0.05），两组在治疗后左室舒张末内径具有明显差异（P＜0.05）。两组在射血分数、缩短分数方面均有明显提高，治疗组在治疗前后具有显著差异（P＜0.01），且治疗后组间差异有统计学意义（P＜0.05）。结论：抗纤益心方能减少扩张型心肌病患者左室舒张末内径、左房内径，提高射血分数及缩短分数，改善患者心脏功能。

This study was aimed to observe the influence of Kang-Xian Yi-Xin (KXYX) formula on the heart size and cardiac function of patients with dilated cardiomyopathy (DCM). A total of 85 cases were randomly divided into the treatment group (43 cases) and the control group (42 cases, with 1 death case). Both groups were treated with routine western medicine. And the KXYX formula was combined in the treatment group once a day. Six months later, changes of the left ventricular end diastolic diameter (LVEDD), left atrial diameter (LAd), ejection fraction (EF) and fractional shortening (FS) were observed by ultrasonography. The results showed that both groups can reduce the LVEDD and Lad. And the effect was obvious in the treatment group (P < 0.05). There was significant difference in the LVEDD of both groups after treatment (P < 0.05). The EF and FS were raised obviously in both groups. There was significant difference before and after treatment in the treatment group (P < 0.01). There was statistical difference between groups after treatment (P < 0.05). It was concluded that the KXYX formula can decrease the LVEDD,Lad, enhance EF and FS, in order to promote the cardiac function of patients with DCM.

河南省教育厅科技攻关项目（2009A360023）：抗纤益心方治疗扩张型心肌病（气虚血瘀证）的临床研究，负责人：曾垂义。